Effect of Tegoprazan Quadruple Therapy on Hp Infected Gastritis

CAI Zhenhua; SU Jiping; ZOU Jiahua

doi:10.14033/j.cnki.cfmr.2025.08.004

Abstract：Objective:To investigate the clinical effect of Tegoprazan quadruple therapy in the treatment of Helicobacter pylori(Hp)infected gastritis.Method:From January to December 2023,112 patients with Hp infected gastritis who treated in Putian No.95 Hospital were taken as the subjects and separated into two groups with 56 patients in each,using a random number table.The control group took quadruple therapy with Rabeprazole,and the observation group received quadruple therapy with Tegoprazan,both group were treated for 2 weeks.The comparisons were performed on the clinical efficacy,pathological changes of gastric mucosa,clinical symptom score,pepsinogen level,comfort level,gastric mucosal inflammation status,Hp eradication rate and adverse reactions in both groups.Result:The observation group achieved higher total effective rate than the control group;compared with the control group,the scores of intestinal metaplasia,gastric mucosa atrophy,clinical symptoms scores and pepsinogen Ⅱ(PGⅡ)level after treatment in the observation group were lower,and the pepsinogen Ⅰ(PGⅠ)level,each dimension of general comfort questionnaire(GCQ)and total scores,disappearance rate of gastric mucosal inflammation and Hp eradication rate after treatment in the observation group were higher,the differences were statistically significant(P<0.05).The comparison of adverse reactions between the two groups was not significantly different(P>0.05).Conclusion:Tegoprazan quadruple therapy can improve the efficacy of Hp infected gastritis patients,better clear Hp,prevent gastric mucosal damage,correct the pepsinogen disorder,promote the disappearance of disease symptoms,and improve patients'comfort,which is safe and reliable.